Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

1.

Metabolic engineering of a haploid strain derived from a triploid industrial yeast for producing cellulosic ethanol.

Rin Kim S, Skerker JM, Iok Kong I, Kim H, Maurer MJ, Zhang GC, Peng D, Wei N, Arkin AP, Jin YS.

Metab Eng. 2017 Feb 16. pii: S1096-7176(16)30200-2. doi: 10.1016/j.ymben.2017.02.006. [Epub ahead of print]

PMID:
28216106
2.

Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.

Kommoss S, Winterhoff B, Oberg A, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J.

Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016. doi: 10.1158/1078-0432.CCR-16-2196. [Epub ahead of print]

PMID:
28159814
3.

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia.

Sfeir JG, Drake MT, LaPlant BR, Maurer MJ, Link BK, Berndt TJ, Shanafelt TD, Cerhan JR, Habermann TM, Feldman AL, Witzig T.

Blood Cancer J. 2017 Feb 3;7(2):e526. doi: 10.1038/bcj.2017.9. No abstract available.

PMID:
28157213
4.

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients.

Rossille D, Azzaoui I, Feldman AL, Maurer MJ, Labouré G, Parrens M, Pangault C, Habermann TM, Ansell SM, Link BK, Tarte K, Witzig TE, Lamy T, Slager SL, Roussel M, Milpied N, Cerhan JR, Fest T.

Leukemia. 2017 Jan 27. doi: 10.1038/leu.2016.385. [Epub ahead of print] No abstract available.

PMID:
28035137
5.

Quantitative Trait Loci (QTL)-Guided Metabolic Engineering of a Complex Trait.

Maurer MJ, Sutardja L, Pinel D, Bauer S, Muehlbauer AL, Ames TD, Skerker JM, Arkin AP.

ACS Synth Biol. 2016 Dec 28. doi: 10.1021/acssynbio.6b00264. [Epub ahead of print]

PMID:
27936603
6.

Sex Differences and Survival in Adults With Bicuspid Aortic Valves: Verification in 3 Contemporary Echocardiographic Cohorts.

Michelena HI, Suri RM, Katan O, Eleid MF, Clavel MA, Maurer MJ, Pellikka PA, Mahoney D, Enriquez-Sarano M.

J Am Heart Assoc. 2016 Sep 29;5(10). pii: e004211.

7.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328.

PMID:
27614696
8.

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK.

Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492.

PMID:
27465588
9.

A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts.

Ghesquières H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, Dupuis J, Link BK, Canioni D, Dogan A, Cozen W, Jarrett RF, Cerhan JR, Salles G.

Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14306. [Epub ahead of print] No abstract available.

PMID:
27716907
10.

Brain potentials predict substance abuse treatment completion in a prison sample.

Fink BC, Steele VR, Maurer MJ, Fede SJ, Calhoun VD, Kiehl KA.

Brain Behav. 2016 May 31;6(8):e00501. doi: 10.1002/brb3.501.

11.

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.

Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G.

Hematol Oncol. 2016 Jun 10. doi: 10.1002/hon.2305. [Epub ahead of print]

PMID:
27282998
12.

Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast.

Maurer MJ, Spear ED, Yu AT, Lee EJ, Shahzad S, Michaelis S.

G3 (Bethesda). 2016 Jul 7;6(7):1853-66. doi: 10.1534/g3.116.027953.

13.

Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.

Parry HM, Damery S, Hudson C, Maurer MJ, Cerhan JR, Pachnio A, Begum J, Slager SL, Fegan C, Man S, Pepper C, Shanafelt TD, Pratt G, Moss PA.

Am J Hematol. 2016 Aug;91(8):776-81. doi: 10.1002/ajh.24403.

14.

Gene Amplification on Demand Accelerates Cellobiose Utilization in Engineered Saccharomyces cerevisiae.

Oh EJ, Skerker JM, Kim SR, Wei N, Turner TL, Maurer MJ, Arkin AP, Jin YS.

Appl Environ Microbiol. 2016 May 31;82(12):3631-9. doi: 10.1128/AEM.00410-16.

15.

APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.

Leonard B, Starrett GJ, Maurer MJ, Oberg AL, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson BD, Brown WL, Kalli KR, Kaufmann SH, Harris RS.

Clin Cancer Res. 2016 Sep 15;22(18):4746-55. doi: 10.1158/1078-0432.CCR-15-2910.

PMID:
27016308
16.

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR.

Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223.

17.

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Gupta M, Stenson M, O'Byrne M, Maurer MJ, Habermann T, Cerhan JR, Weiner GW, Witzig TE.

Ann Oncol. 2016 Jan;27(1):165-72. doi: 10.1093/annonc/mdv486.

18.

Engineering Rhodosporidium toruloides for increased lipid production.

Zhang S, Skerker JM, Rutter CD, Maurer MJ, Arkin AP, Rao CV.

Biotechnol Bioeng. 2016 May;113(5):1056-66. doi: 10.1002/bit.25864.

PMID:
26479039
19.

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, Witzig TE, Weiner GJ, Feldman AL, Dogan A, Cunningham JM, Olswold CL, Molina TJ, Link BK, Milpied N, Cox DG, Salles GA, Cerhan JR.

J Clin Oncol. 2015 Nov 20;33(33):3930-7. doi: 10.1200/JCO.2014.60.2573.

20.

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.

Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, Radisky ES.

Oncotarget. 2015 Nov 3;6(34):35737-54. doi: 10.18632/oncotarget.5927.

Items per page

Supplemental Content

Loading ...
Support Center